BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24920885)

  • 1. Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position.
    Winter E; Gozzi GJ; Chiaradia-Delatorre LD; Daflon-Yunes N; Terreux R; Gauthier C; Mascarello A; Leal PC; Cadena SM; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
    Drug Des Devel Ther; 2014; 8():609-19. PubMed ID: 24920885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity.
    Rangel LP; Winter E; Gauthier C; Terreux R; Chiaradia-Delatorre LD; Mascarello A; Nunes RJ; Yunes RA; Creczynski-Pasa TB; Macalou S; Lorendeau D; Baubichon-Cortay H; Ferreira-Pereira A; Di Pietro A
    Drug Des Devel Ther; 2013; 7():1043-52. PubMed ID: 24109177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
    Valdameri G; Gauthier C; Terreux R; Kachadourian R; Day BJ; Winnischofer SM; Rocha ME; Frachet V; Ronot X; Di Pietro A; Boumendjel A
    J Med Chem; 2012 Apr; 55(7):3193-200. PubMed ID: 22449016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
    Juvale K; Pape VF; Wiese M
    Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
    Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
    J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
    Sim HM; Lee CY; Ee PL; Go ML
    Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
    Guragossian N; Belhani B; Moreno A; Nunes MT; Gonzalez-Lobato L; Marminon C; Berthier L; Rocio Andrade Pires AD; Özvegy-Laczka C; Sarkadi B; Terreux R; Bouaziz Z; Berredjem M; Jose J; Di Pietro A; Falson P; Le Borgne M
    Eur J Med Chem; 2021 Feb; 211():113017. PubMed ID: 33223263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
    Liu XL; Tee HW; Go ML
    Bioorg Med Chem; 2008 Jan; 16(1):171-80. PubMed ID: 17964170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
    Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
    Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Juvale K; Gallus J; Wiese M
    Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
    Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 5-Hydroxy-3',4',7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance.
    Tsunekawa R; Katayama K; Hanaya K; Higashibayashi S; Sugimoto Y; Sugai T
    Chembiochem; 2019 Jan; 20(2):210-220. PubMed ID: 30187992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
    Marighetti F; Steggemann K; Hanl M; Wiese M
    ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
    Zhang Y; Laterra J; Pomper MG
    Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
    Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
    Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of inhibitors of BCRP/ABCG2.
    Juvale K; Wiese M
    Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
    Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
    Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.